Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California

Background: Pazopanib was approved for advanced soft tissue sarcoma as a second- or third-line therapy based on the clinical trial “Pazopanib for metastatic soft-tissue sarcoma” (PALETTE). We hypothesized that the real-world experiences may be significantly different from the clinical trial results....

Descripción completa

Detalles Bibliográficos
Autores principales: Seto, Tiffany, Song, Mee-Na, Trieu, Maily, Yu, Jeanette, Sidhu, Manpreet, Liu, Chi-Mei, Sam, Danny, Pan, Minggui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473235/
https://www.ncbi.nlm.nih.gov/pubmed/30889920
http://dx.doi.org/10.3390/medsci7030048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473235/
https://www.ncbi.nlm.nih.gov/pubmed/30889920
http://dx.doi.org/10.3390/medsci7030048

Ejemplares similares